CN111417391B - 用于抑制肿瘤生长的材料和方法 - Google Patents

用于抑制肿瘤生长的材料和方法 Download PDF

Info

Publication number
CN111417391B
CN111417391B CN201880076756.0A CN201880076756A CN111417391B CN 111417391 B CN111417391 B CN 111417391B CN 201880076756 A CN201880076756 A CN 201880076756A CN 111417391 B CN111417391 B CN 111417391B
Authority
CN
China
Prior art keywords
cancer
formulation
free amino
amino acids
anoctamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880076756.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111417391A (zh
Inventor
S·维德亚瑟格
R·古普塔
S·加托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylev Ltd
University of Florida Research Foundation Inc
Original Assignee
Entelinco LLC
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelinco LLC, University of Florida Research Foundation Inc filed Critical Entelinco LLC
Priority to CN202410201525.5A priority Critical patent/CN118078810A/zh
Publication of CN111417391A publication Critical patent/CN111417391A/zh
Application granted granted Critical
Publication of CN111417391B publication Critical patent/CN111417391B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880076756.0A 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法 Active CN111417391B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410201525.5A CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410201525.5A Division CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Publications (2)

Publication Number Publication Date
CN111417391A CN111417391A (zh) 2020-07-14
CN111417391B true CN111417391B (zh) 2024-06-18

Family

ID=64049688

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880076756.0A Active CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法
CN202410201525.5A Pending CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410201525.5A Pending CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Country Status (7)

Country Link
US (1) US12109191B2 (https=)
EP (1) EP3691628A1 (https=)
JP (2) JP7352901B2 (https=)
KR (1) KR102709096B1 (https=)
CN (2) CN111417391B (https=)
CA (1) CA3078335A1 (https=)
WO (1) WO2019070750A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
WO2019224428A1 (en) * 2018-05-22 2019-11-28 Seleq Oy Pharmaceutical compositions for the treatment of cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
WO2017053328A1 (en) * 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) * 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
WO1993006934A1 (en) 1991-09-30 1993-04-15 Devtech Labs, Inc. Electrostatic separation of plastic materials
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
DE69229910T2 (de) 1991-10-07 2000-04-20 Otsuka Pharmaceutical Factory, Inc. Enterale zubereitungen zur krebstherapie
JP3429327B2 (ja) 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20060052454A1 (en) * 2004-08-09 2006-03-09 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders
MX350541B (es) 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
WO2017053328A1 (en) * 2015-09-21 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2;Yohan Seo等;《PLoS One》;20160524;第24卷(第11期) *
Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells;Yohan Seo等;《PLoS One》;20170331;第12卷(第3期) *
New selective inhibitors of calcium-activated chloride channels - T16A(inh) -A01, CaCC(inh) -A01 and MONNA - what do they inhibit?;D M B Boedtkjer等;《British Journal of Pharmacology》;20150708;第172卷(第16期) *

Also Published As

Publication number Publication date
JP2023171755A (ja) 2023-12-05
US12109191B2 (en) 2024-10-08
JP7352901B2 (ja) 2023-09-29
KR102709096B1 (ko) 2024-09-23
JP2020536096A (ja) 2020-12-10
US20200323820A1 (en) 2020-10-15
CN111417391A (zh) 2020-07-14
KR20200060492A (ko) 2020-05-29
EP3691628A1 (en) 2020-08-12
CA3078335A1 (en) 2019-04-11
CN118078810A (zh) 2024-05-28
WO2019070750A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
CN111417391B (zh) 用于抑制肿瘤生长的材料和方法
JP7095028B2 (ja) 薬学的組成物及び方法
TWI730013B (zh) 用於治療癌症的四環喹諾酮類似物組合療法
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
RU2638795C2 (ru) Способ введения противоопухолевого агента
WO2019126739A1 (en) Pyrvinium pamoate anti-cancer therapies
EP3027191A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
TW201330845A (zh) 胰臟癌及／或膽道癌治療劑
JP2023018029A (ja) 癌の処置のための医薬組成物および方法
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
US20220313702A1 (en) Oxathiazin compounds for inhibiting gapdh
JP2022553175A (ja) がんの処置における使用のためのα－メチル－ＤＬ－チロシンのアルキルエステル
JP2022542725A (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
US11992478B2 (en) Methods of using androgen receptor inhibitors as cancer therapeutics
US20240122937A1 (en) Treating cancer in patient with pten inactivating mutation
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2020199973A1 (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN103826645A (zh) 砷在癌症治疗保护中的用途
CN101653608B (zh) 含有肝细胞生长因子受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
KR20260049608A (ko) 아자 2 고리형 화합물과 항안드로겐제를 사용한 암 병용 요법
WO2024071464A1 (ko) 말레이트 금속염을 포함하는 항암용 조성물
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合
HK40060452A (en) COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG
HK1126133A (en) Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230417

Address after: Fla

Applicant after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Applicant after: Entelinco LLC

Address before: Fla

Applicant before: University OF FLORIDA RESEARCH FOUNDATION, INC.

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Florida, USA

Patentee after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region after: U.S.A.

Patentee after: Amylev Limited

Address before: Florida, USA

Patentee before: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region before: U.S.A.

Patentee before: Entelinco LLC